



Attorney Docket No. 17a 270.PFUS  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dahl et al.

Serial No.: 10/540,794

Group No.: 1616

Filed: March 20, 2006

Examiner: Pryor, Alton N.

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE  
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE  
OF ALLOWANCE (37 CFR 1.97 (c))**

**TIME TRANSMITTAL OF ACCOMPANYING INFORMATION  
DISCLOSURE STATEMENT**

1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311,

whichever occurs first.

---

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Sharon A. Lira

(Type or print name of person mailing paper)

Date:

January 17, 2007

(Signature of person mailing paper)

**CERTIFICATION OR FEE**

2. Accompany this transmittal is

A. ☐ a certification as specified in 37 CFR 1.97 (e)

**OR**

B. ☒ the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$180.00).

**FEE PAYMENT**

3. Applicant elects the option to pay the fee set forth in 37 CFR 1.17 (p) for submission of an information disclosure statement under § 1.97 (c). (\$180.00).

Fee due \$ 180.00

**METHOD OF PAYMENT OF FEE**

4.

☐ attached is check in the sum of \$ \_\_\_\_\_

☒ charge Account No. 07-1250 the sum of \$ 180.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account No. 07-1250

Reg. No. 27,043

Tel. No.: (650 ) 522-5535



**SIGNATURE OF ATTORNEY**

Max Hensley

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404



Attorney Docket No. 270.PFUS  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dahl et al.

Serial No.: 10/540,794

Group No.: 1616

Filed: March 20, 2006

Examiner: Pryor, Alton N.

For: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Commissioner for Patents  
Mail Stop Amendment  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement.**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☐ Identification of Prior Application in Which Listed Information Was Already Cited.

---

**CERTIFICATE OF MAILING**

I hereby certify that this Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☒ 37 CFR 1.8 (a)  
with sufficient postage as  
first class mail

or

☐ 37 CFR 1.10  
as "Express Mail Post  
Office to Addressee" Mailing  
Label  
No. \_\_\_\_\_

Date: \_\_\_\_\_

January 17, 2007

Sharon Lira  
(Type or print name of person mailing paper)

[Signature]  
(Signature of person mailing paper)

01/22/2007 JBALINAH 00000061 071250 10540794

01 FC:1806 180.00 DA

## Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted


This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No.:	60/440,308	filed on	January 14, 2003
Serial No.:	60/440,246	filed on	January 14, 2003

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043

Tel. No.: (650 ) 522-5535

  
\_\_\_\_\_  
SIGNATURE OF ATTORNEY  
Max L. Hensley  
\_\_\_\_\_  
Type or print name of attorney  
Gilead Sciences, Inc.  
333 Lakeside Drive  
\_\_\_\_\_  
P.O. Address  
Foster City, CA 94404  
\_\_\_\_\_

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(37 CFR 1.98(b))

Sheet 1 of 1


ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540,794

APPLICANT: Dahl et al

FILING DATE: 3/20/2006

GROUP ART UNIT: 1616

EXAMINER NAME:

**U.S. PATENT DOCUMENTS**

Examiner initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T

**NON PATENT LITERATURE DOCUMENTS**

Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		DE CLERCQ E., "Highlights in the Development of New Antiviral Agents", 2(2): 163-175, MINI REV MED CHEM, 2002	
		DE CLERCQ E., "New Developmentss in anti-HIV chemotherapy", 56(1-2): 3-12, Farmaco, 2001	
		DE CLERCQ E., "New Development in Anti-HIV Chemotherapy", 8(13):1543-72, CURRENT MEDICINAL CHEMISTRY, 2001	
		ISHIDA K, ASAO T., "Self-association and Unique DNA Binding Properties of the Anti-Cancer Agent TAS-103, a Dual Inhibitor of Topoisomerases I and II", 1587(2-3):155-163, BIOCHEM BIOPHYS ACTA, 2002	
		LIU ET AL., "Thymidylate Synthase as a Translational Regulator of Cellular Gene Expression.", 1587(2-3):174-182, BIOCHEM BIOPHYS ACTA, 2002	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.